Discussion about this post

User's avatar
Neural Foundry's avatar

Really solid synthesis here. The XBI recovery angle caught my attention tho. 85% from April lows is impressive, but the more interesting part is how AI-accelerated discvoery is changing the biotech investment thesis itself. I've been watching how the timeline compression from years to months affects valuations. When a startup can validate a drug target in 6 months instead of 3 years, suddenly the discount rate math changes completely. Stanford's CRISPR-GPT is kinda the sleeper story here becuase it's not just faster discovery, it's democratizing gene therapy development to smaller labs who couldn't afford traditional timelines.

Expand full comment

No posts

Ready for more?